Adrenal Cortex Carcinoma

P1, N=70, Active, not recruiting, Eisai Co., Ltd. | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Mar 2027

identifying agents capable of complementing or replacing standard therapy remains a central challenge in ACC research. Our findings suggest that celastrol is a potent bioactive compound with activity against both monolayer and 3D ACC models, offering potential translational relevance. By elucidating ER stress as a shared mechanism between celastrol and mitotane, our work supports further exploration of this pathway as a strategy to potentially improve therapeutic outcomes in ACC patients.

The patient was started on mitotane and metyrapone, followed by 8 cycles of etoposide-doxorubicin-cisplatin plus mitotane. The patient underwent complete surgical resection, achieving full remission. More than 1 year later, she remains disease free.

P2, N=48, Recruiting, National Cancer Institute (NCI) | Initiation date: Jul 2026 --> Feb 2026

As primary treatment is chemotherapy, accurate diagnosis on limited material such as FNAC is critical. The recognition of cytological features and follow up with appropriate ancillary testing has the potential to improve management of these patients.

P2, N=21, Recruiting, Emory University | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027

This report suggests that RET variants in MEN2A patients from the Chinese population may differ from the common RET variants. Additionally, MEN2A patients may present with thyroid follicular epithelial-derived tumors; however, further studies are necessary to determine any potential associations with RET variants.

P1, N=15, Not yet recruiting, Daiichi Sankyo Inc.

The presence of anaplastic features poses a high risk of misdiagnosis as a sarcoma or carcinoma, potentially leading to overly aggressive therapy. Therefore, we advocate for the inclusion of this entity in the differential diagnosis of adrenal neoplasms and recommend routine ALK testing in similar challenging cases to guide precise management and avoid therapeutic errors.

P2, N=30, Completed, Sparrow Pharmaceuticals | Terminated --> Completed

Intraoperatively, tumour manipulation precipitated abrupt hypertensive surges with bradycardia, necessitating nitroglycerine and sodium nitroprusside infusion. Intraoperative haemodynamic instability during adrenal manipulation should raise suspicion of catecholamine secretion, even in the absence of classical symptoms. The report emphasises the importance of invasive monitoring and anaesthetic preparedness to manage unexpected catecholamine release.

P=N/A, N=1500, Recruiting, St. Jude Children's Research Hospital | N=3000 --> 1500